| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.085 | 0.08 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.08 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.09 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.1 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.1 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.074 | 0.1 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.1 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | 0.062 | 0.1 |